Update (18/11/2019): French biotech Valneva has revealed additional phase I results concerning its experimental chikungunya vaccine; all 68 patients that…
European biotechnology company Valneva and UK company Immune Targeting Systems (ITS) announced that they have signed an exclusive worldwide commercial…